The present invention relates to the direct binding and interaction study of SP-D with human eosinophils from hypereosinophilic patients and healthy controls and the differential modulation of both type of eosinophils by SP-D. The invention provides the use of human lung surfactant protein-D (SP-D) in the modulation of activity of human eosinophils derived from hypereosinophilic patients to an increased activation state towards apoptosis, while increasing the survival of eosinophils from healthy controls. The invention also relates to the use of SP-D to increased uptake and clearance of apoptotic eosinophils by macrophages. Accordingly the utility of the invention can be extended in human subjects suffering with eosinophilic mediated diseases and disorders for resolution of eosinophilic inflammations in neuromuscular diseases with eosinophilia, hypereosinophilic leukemias, hypereosinophilc syndromes (rare hematological diseases), skin diseases like eosinophilia-Myalgia syndrome, eosinophilic fascitis, capillary leak syndromes (IL-2), Churg-Strauss syndrome, toxic oil syndrome, parasitosis, etc., where a large number of stimulated eosinophils accumulate and release a series of growth factors, cytokines, chemokines, bioactive lipid mediators, toxic oxygen metabolites.
